Specialized care for pancreatic adenocarcinoma and neuroendocrine tumors with advanced chemotherapy, targeted therapy, and comprehensive supportive care.
Expert management of pancreatic adenocarcinoma and neuroendocrine tumors with FOLFIRINOX, gemcitabine-based regimens, targeted therapies, and comprehensive palliative care. We focus on symptom management and quality of life.
Multiphase CT, MRI/MRCP, and endoscopic ultrasound for accurate staging and resectability assessment.
CA19-9, CEA, chromogranin A, and molecular profiling for treatment selection and monitoring.
Core needle biopsy, immunohistochemistry, and genetic testing for personalized treatment.
Dull, persistent upper abdominal or back pain; worsens after meals or when lying down.
Yellowing of skin/eyes, dark urine, pale stools, and itching due to bile duct obstruction.
Unintended weight loss, loss of appetite, nausea, new-onset diabetes in some cases.
Smoking, obesity, chronic pancreatitis, long-standing diabetes increase risk.
BRCA1/2, PALB2, Lynch syndrome, family history of pancreatic cancer.
Pancreatic cysts, hereditary pancreatitis, exposure to certain chemicals.
Regular CA19-9 monitoring, imaging studies, and symptom assessment for treatment optimization.
Collaboration with pancreatic surgery, gastroenterology, and palliative care specialists.
Managing treatment side effects, nutritional status, and maintaining comfort throughout treatment.